Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Breast Cancer
The latest analysis from the phase III NATALEE trial demonstrated that adding ribociclib (Kisqali) to endocrine therapy improved rates of ...
Read moreDetailsThe latest analysis from the phase III NATALEE trial demonstrated that adding ribociclib (Kisqali) to endocrine therapy improved rates of ...
Read moreDetails© 2023 earth-news.info
© 2023 earth-news.info